APA (7th ed.) Citation

HJ, C., HY, T., Y, H., Y, F., G, W., S, C., . . . YL, W. (2025). A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001). Journal of hematology & oncology, 18(1), 3. https://doi.org/10.1186/s13045-024-01656-0

Chicago Style (17th ed.) Citation

HJ, Chen, et al. "A Phase II Trial of Anlotinib Plus EGFR-TKIs in Advanced Non-small Cell Lung Cancer with Gradual, Oligo, or Potential Progression After EGFR-TKIs Treatment (CTONG-1803/ALTER-L001)." Journal of Hematology & Oncology 18, no. 1 (2025): 3. https://doi.org/10.1186/s13045-024-01656-0.

MLA (9th ed.) Citation

HJ, Chen, et al. "A Phase II Trial of Anlotinib Plus EGFR-TKIs in Advanced Non-small Cell Lung Cancer with Gradual, Oligo, or Potential Progression After EGFR-TKIs Treatment (CTONG-1803/ALTER-L001)." Journal of Hematology & Oncology, vol. 18, no. 1, 2025, p. 3, https://doi.org/10.1186/s13045-024-01656-0.